Ireland
--:--IST
Starting soon Not applicable

Effect of Narrative Education on Glycemic Control in Adults With Type 2 Diabetes in Primary Care

NCT07307430 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2026-02-15
Last updated
2025-12-31

Condition(s) studied

Type 2 Diabetes Mellitus (T2DM)Diabetes Self-managementDiabetes Education

Investigational drug(s) / intervention(s)

Structured Narrative Education Program

Structured Narrative Education Program: Two individual face-to-face narrative sessions (20-30 minutes) at Day 0 and Day 15 plus four brief reinforcement phone calls (3-5 minutes) at Days 30, 45, 60, and 75 to support diabetes self-care goal setting and adherence.

Study summary

Type 2 diabetes is common in primary care, and daily self-care behaviors are essential for achieving blood sugar targets. This randomized, two-arm clinical trial will evaluate whether a structured narrative education program added to usual diabetes care improves glycemic control compared with usual care alone in adults with type 2 diabetes. Eligible participants (age ≥18 years) with suboptimal glycemic control (HbA1c ≥7.0% in the last 3 months) will be randomized 1:1 to either standard care or standard care plus narrative education. The narrative education program will be delivered by a family physician over 3 months and includes two individual face-to-face sessions (approximately 20-30 minutes) at Day 0 and Day 15 and four brief telephone reinforcement calls (approximately 3-5 minutes) on Days 30, 45, 60, and 75.

The primary outcome is the absolute change in HbA1c from baseline (Day 0) to Day 90. Secondary outcomes include changes in diabetes self-care activities (SDSCA-TR), diabetes-related distress (PAID-5-TR), and body mass index (BMI) from Day 0 to Day 90.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥ 18 years * Diagnosis of type 2 diabetes mellitus for at least 1 year * HbA1c ≥ 7.0% measured within the last 3 months prior to enrollment * Followed in the study family health center and reachable by telephone * Able to read and write (or able to complete questionnaires with investigator assistance) * Provides written informed consent Exclusion Criteria: * Type 1 diabetes, gestational diabetes, or secondary diabetes * Acute infection or hospitalization within the last 2 weeks * Major surgery or blood transfusion within the last 3 months * Active malignancy or current systemic steroid/immunosuppressive therapy * Significant cognitive impairment preventing participation * Current participation in another structured diabetes education program

Primary outcome measure(s)

  • Change in HbA1c (%) — Baseline (Day 0) to Day 90
    Absolute change in glycated hemoglobin (HbA1c) from baseline (Day 0) to Day 90.

Trial sites (1)

FacilityCityRegionStatus
Ozerli Family Health Center No. 4 Antakya Hatay
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07307430 on ClinicalTrials.gov ↗ ← All trials in Turkey